Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT)
2022-502845-83-00Phase 2Completed
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in catecholaminergic polymorphic ventricular tachycardia (CPVT) comparing CRD-4730 with Placebo (2 arms). Primary endpoint: Safety and tolerability of CRD-4730. Started Mar 2024; status: completed.
02
Drugs
CRD-4730
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on 2022-502845-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502845-83-00.